Myelodysplastic syndromes: A community hospital-based study of prognostic factors and international prognostic scoring system

Connecticut Medicine

Volumn 65, Issue 8, 2001, Pages 455-463

  Mirza, Imran ^a   Garzón, Ramiro ^b   Burns, Jacqueline ^b   Edwards, Leonel ^b   Fernandez Cymering, Cecilia ^b   Kloss, Robert ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHI SQUARE DISTRIBUTION; CLASSIFICATION; COMMUNITY HOSPITAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK; SURVIVAL; UNITED STATES;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FEMALE; HOSPITALS, COMMUNITY; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OHIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS;

EID: 0035434512     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Todd WM, Pierre RV: Preleukemia: A long-term prospective study of 326 patients (abstract). Blood 1983; 62:184.
2. Bennet JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
3. Foucar K, Langdon RM II, Armitage JO, et al: Myelodysplastic Syndromes: A clinical and pathologic analysis of 109 cases. Cancer 1985; 56:553-61.
4. Kerkhofs H, Hermans J, Haak HL, et al: Utility of the FAB classification for the myelodysplastic syndromes: Investigation of prognosis factors in 237 cases. Br J Haematol 1987; 65:73-81.
5. Vallespi T, Imbert M, Mecucci C, et al: Diagnosis, classification and cytogenetics of Myelodysplastic syndromes. Haematologica 1998; 83:258-75.
6. Parlier V, Van Melle G, Beris P, et al: Hematological, clinical and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosomal findings. Cancer Genet Cytogenet 1994; 78:219-31.
7. Solé F, Prietto F, Badia L, et al: Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genetic Cytogenet 1992; 64:12-20.
8. Suciu S, Kuse R, Weh HJ, et al: Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genetic Cytogenet 1990; 44:15-26.
9. Sanz GF, Sanz MA, Vallespi T, et al: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395-408.
10. Sanz GF, Sanz MA, Greenberg PL: Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998; 83:358-68.
11. Greenberg P, Cox C, Le Beau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
12. Maes B, Meeus P, Michaux L, et al: Application of the international prognostic scoring system for myelodysplastic syndromes. Ann Oncol 1999; 10:825-9.
13. Jaiyesimi IA, Friedline JA, Mattson JC, et al: Myelodysplastic syndrome at a large tertiary care community hospital: Analysis according to the international prognostic scoring system. Leuk Res 2000; 24:417-26.
14. Lee JJ, Kim HJ, Chung IJ, et al: Comparisons of prognostic scoring systems for myelodysplastic syndromes: A Korean multicenter study. Leuk Res 1999; 23:425-32.
15. Pfeilstöcker M, Reisner R, Nösslinger T, et al: Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 1999; 106:455-63.
16. Mitelman F(ed). ISCN (1995): An International System for Human Cytogenetics Nomenclature. Basel, Switzerland, Karger, 1995.
17. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 3:457-81.
18. Cox DR: Regression models and life tables. J Royal Stat Soc 1972; 34:187-220.
19. Mufti GJ, Stevens JR, Oscier DG, et al: Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 1985; 59:425-33.
20. Morel P, Hebbar M, Lai JL, et al: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report of 408 cases. Leukemia 1993; 7:1315-23.
21. Aul C, Gattermann N, Heyll A, et al: Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6:52-59.
22. Toyama K, Ohyashiki K, Yoshida Y, et al: Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicenter study in Japan. Leukemia 1993; 7: 499-508.
23. Greenberg PL: Risk factors and their relationship to prognosis in myelodysplastic syndromes. Leuk Res 1998; 22:83-6.
24. Estey E, KeatingM , Pierce S, et al: Application of the international scoring system for myelodysplasia to M.D. Anderson patients. Blood 1997; 90:2843-4.
25. Balduini CL, Guarnone R, Pecci A, et al: The myelodysplastic syndromes: Predictive value of eight prognostic systems in 143 cases from a single institution. Haematologica 1999; 84:12-6.
26. Balduini CL, Guarnone R, Pecci A, et al: International prognostic scoring system and other prognostic scoring systems for myelodysplastic syndromes. Blood 1997; 90:4232-3.
27. Solé F, Espinet B, Sanz GF, et al: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000; 108:346-56.
28. Morel P, Declercq C, Hebbar M, et al: Prognostic factors in myelodysplastic syndromes: Critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996; 94: 116-9.
29. Rios A, Cañizo MC, Sanz MA, et al: Bone marrow biopsy in myelodysplastic syndromes: Morphologic characteristics and contribution to the study of prognostic factors. Br J Haematol 1990; 75:26-33.
30. Tuzuner N, Cox C, Rowe JM, et al: Hypocellular myelodysplastic syndromes (MDS): New proposals. Br J Haematol 1995; 91:612-617.
31. Tricot G, De Wolf-Peeters C, Hendrickx B, et al: Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 1984; 57:423-30.
32. Tricot G, De Wolf-Peeters C, Hendrickx B, et al: Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984; 58:217-25.
33. Maschek H, Gutzmer R, Choritz H, et al: Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haematol 1994; 53:280-7.
34. Knapp R, Dewald GW and Pierre RV: Cytogenetics studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985; 60:507-16.
35. Boulnood J, Fidler C: Chromosomal deletions in myelodysplasia. Leuk Lymph 1995; 17:71-8.
36. Jacobs RH, Cornbleet MA, Vardiman JW, et al: Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986; 67:1765-72.
37. Yunis JJ, Lobell M, Arnesen MA, et al: Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukemia. Br J Haematol 1988; 68:189-94.